Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

MV-130 is under clinical development by Inmunotek and currently in Phase II for Lower Respiratory Tract Infections.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

GMA-106 is under development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). The drug candidate is being developed based on Bibody platform. It acts by ...

MyMD-1 is under clinical development by TNF Pharmaceuticals and currently in Phase I for Hashimoto Thyroiditis.

CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase I for Kaposi Sarcoma.

Q-901 is under clinical development by Qurient and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase ...

Avelumab is under clinical development by Merck and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) ...

Regdanvimab is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

PF-06835919 is under clinical development by Pfizer and currently in Phase II for Unspecified Metabolic Disorders.